Evidence map›Paper›PMID 39698258›Full record

ArticleACS pharmacology & translational science2024

A Comparative Pharmacokinetics Study of Orally and Intranasally Administered 8-Nitro-1,3-benzothiazin-4-one (BTZ043) Amorphous Drug Nanoparticles.

Feng Li, Franziska Marwitz, David Rudolph, Wiebke Gauda, Michaela Cohrs, Paul Robert Neumann, Henrike Lucas, Julia Kollan, Ammar Tahir, Dominik Schwudke and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Feng LiDepartment of Pharmaceutical Sciences, Division of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.
Franziska MarwitzDivision of Bioanalytical Chemistry, Research Center Borstel, Leibniz Lung Center, Borstel 23845, Germany.
David RudolphInstitute of Inorganic Chemistry, Karlsruhe Institute of Technology (KIT), Engesserstraße 15, Karlsruhe 76131, Germany.
Wiebke GaudaDivision of Bioanalytical Chemistry, Research Center Borstel, Leibniz Lung Center, Borstel 23845, Germany.
Michaela CohrsLaboratory for General Biochemistry and Physical Pharmacy, Ghent University, 9000 Gent, Belgium.ORCID https://orcid.org/0000-0003-1195-534X
Paul Robert NeumannDepartment of Pharmaceutical Technology and Biopharmaceutics, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale) 06120, Germany.
Henrike LucasDepartment of Pharmaceutical Technology and Biopharmaceutics, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale) 06120, Germany.
Julia KollanDepartment of Pharmaceutical Technology and Biopharmaceutics, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale) 06120, Germany.
Ammar TahirDepartment of Pharmaceutical Sciences, Division of Pharmacognosy, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.ORCID https://orcid.org/0000-0003-3682-5680
Dominik SchwudkeDivision of Bioanalytical Chemistry, Research Center Borstel, Leibniz Lung Center, Borstel 23845, Germany.ORCID https://orcid.org/0000-0002-1379-9451
Claus FeldmannInstitute of Inorganic Chemistry, Karlsruhe Institute of Technology (KIT), Engesserstraße 15, Karlsruhe 76131, Germany.ORCID https://orcid.org/0000-0003-2426-9461
Gabriela HädrichDepartment of Pharmaceutical Sciences, Division of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.
Lea Ann DaileyDepartment of Pharmaceutical Sciences, Division of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.ORCID https://orcid.org/0000-0002-4908-7122

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BTZ043 is an 8-nitro-1,3-benzothiazin-4-one with potency against multidrug-resistant

Identifiers

PMID39698258
PMCPMC11651166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.